Swine fever vaccine market
Swine Fever Vaccine Market, by Type (African Swine Fever and Classical Swine Fever), by Vaccine Type (Live-Attenuated, Chimeric (Live-attenuated or inactivated), Subunit or vector system based, and Replicon vaccine), by Distribution Channel (Public and Private), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2024 - 2031
- Mar 2024
- CMI5195
- 156 Pages
- Excel & Pdf
- Biotechnology
African swine fever (ASF) and classical swine fever (CSF) are highly contagious viral diseases of pigs. They are clinically identical and cannot be definitively distinguished from one other in the field. A diagnosis must be verified by laboratory tests. These diseases may seem to be identical; however, they are caused by totally unrelated viruses. CSF, often called as 'hog cholera', is caused by a virus from the pestivirus genus of the family Flaviviridae and is closely related to the virus that causes bovine viral diarrhea (mucosal disease) in cattle and border disease (hairy shaker disease) in sheep. The virus that causes ASF is unrelated to the virus that causes classical swine fever and has a more complex genetic makeup. Pigs are the only animals affected by both ASF and CSF; humans and other animals are not affected by these diseases.
The global swine fever vaccine market is estimated to be valued at USD 3,028.7 Mn in 2024 and is expected to exhibit a CAGR of 5.9% during the forecast period (2024-2031).
Figure 1. Global Swine Fever Vaccine Market Value (USD MN), by Region, 2024
Increasing outbreaks of swine fever are expected to drive the swine fever vaccine market growth.
The increasing outbreaks of swine fever is expected to drive the market growth over the forecast period. For instance, as of May 9, 2022, 259 pigs have died in Meghalaya’s Ri-Bhoi district in India due to African Swine Fever (ASF), according to a senior official of the Veterinary and Animal Husbandry Department. The first outbreak was reported by the Veterinary department on April 13, 2022 following which instructions were issued under the Prevention and Control of Infectious and Contagious Diseases in Animals Act, 2009, banning movement of pigs, slaughter, and supplies at Umshorshor village, Meghalaya, India, and within 10 km of its vicinity.
Swine Fever Vaccine Market Report Coverage
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2023 | Market Size in 2024: | US$ 3,028.7 Mn |
Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
Forecast Period 2024 to 2031 CAGR: | 5.9% | 2031 Value Projection: | US$ 4,536.4 Mn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
Merck & Co., Inc. (Merck Animal Health), Ceva, Zoetis Services LLC, Boehringer Ingelheim International GmbH, Indian Immunologicals Ltd., Bioveta, a.s., Komipharm, and EC21 Inc. |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Figure 2. Global Swine Fever Vaccine Market Share, By Vaccine Type, 2024
Recent Developments
In May 2022, Boehringer Ingelheim, a global leading company in animal health, announced its latest innovation: TwistPak, a revolutionary mixing platform. It enables swine producers to combine two vaccines, Ingelvac CircoFLEX and Ingelvac MycoFLEX, in a convenient, fast and flexible way.
In June 2020, Boehringer Ingelheim announced that it’s China-developed Classical Swine Fever Vaccine, Live (C-strain, PK/WRL Cell Line Origin) (English commercial name: Ingelvac CSF MLV) has just received a "New Veterinary Drug Registration Certificate" from the Ministry of Agriculture and Rural Affairs of China. It is the first Classical Swine Fever live vaccination co-developed by a foreign corporation and Chinese research organizations.
Increasing research and development activities by government and non-government organizations and key players in the market are expected to drive the market growth during the forecast period.
Increasing efforts by the governments of various countries and key players in the market to develop swine fever vaccines are expected to drive the market growth over the forecast period. For instance, in June 2022, Vietnam had developed an African swine fever vaccine, NAVET-ASFVAC, for pigs in partnership with the U.S. The Vietnamese researchers worked with the U.S. scientists on the NAVET-ASFVAC jab since 2020.
Global Swine Fever Vaccine Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.
The coronavirus pandemic had negatively impacted the development, production, and supply of medicines and the growth of the pharmaceutical businesses of various companies across the globe. The lockdown has resulted in the closure of industrial establishments, except for the manufacturing of essential commodities, and there has been a disruption in the supply chain of pharmaceuticals. Thus, the COVID-19 pandemic had affected the economy in three main ways: 1) by directly affecting the production and demand; 2) disrupting distribution channels; 3) causing a financial impact on firms and financial markets.
Supply chain and manufacturing activities in India, China, and the U.S. were disrupted due to the global lockdown, while many countries such as Saudi Arabia, the UAE, Egypt, and others are facing problems with regard to the transportation of drugs and vaccines from one place to another. Due to all these reasons, the growth of the global swine fever vaccine market was negatively hampered.
Global Swine Fever Vaccine Market: Restraint
The major factors that hinder the growth of the global swine fever vaccine market include stringent regulatory approvals. The federal agencies involved in the approval of animal medicines are the United States Department of Agriculture (USDA) (biologics such as vaccines), the U.S. Food and Drug Administration (pharmaceuticals), and the Environmental Protection Agency (EPA) (pesticides such as flea and tick medicine). While undergoing approval, animal medicines are vigorously researched and tested for safety, purity, and efficacy, a process that can take five to seven years and cost tens of millions of dollars. Thus, stringent regulatory approvals may act as a restraint for the market growth.
Key Players
Major players operating in the global swine fever vaccine market include Merck & Co., Inc. (Merck Animal Health), Ceva, Zoetis Services LLC, Boehringer Ingelheim International GmbH, Indian Immunologicals Ltd., Bioveta, a.s., Komipharm, and EC21 Inc.
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Vaccine Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Epidemiology
- Regulatory Scenario
- PEST Analysis
- New Product Approval/Launch
- Market Dynamics
- Global Swine Fever Vaccine Market - Impact of Coronavirus (COVID-19) Pandemic
- Economic Impact
- COVID-19 Epidemiology
- Demand and Supply Analysis
- Global Swine Fever Vaccine Market, By Type, 2019 – 2031, (US$ Million)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 – 2031
- Segment Trends
- African Swine Fever
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (US$ Million)
- Classical Swine Fever
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (US$ Million)
- Overview
- Global Swine Fever Vaccine Market, By Vaccine Type, 2019 – 2031, (US$ Million)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 – 2031
- Segment Trends
- Live-Attenuated
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (US$ Million)
- Chimeric (Live-attenuated or inactivated)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (US$ Million)
- Subunit or vector system based
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (US$ Million)
- Replicon vaccine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (US$ Million)
- Overview
- Global Swine Fever Vaccine Market, By Distribution Channel, 2019 – 2031, (US$ Million)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 – 2031
- Segment Trends
- Public
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (US$ Million)
- Private
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (US$ Million)
- Overview
- Global Swine Fever Vaccine Market, By Region, 2019 – 2031, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, By Region, 2020–2031
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 – 2031, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 – 2031, (US$ Million)
- North Africa
- Central Africa
- South Africa
- Introduction
- Competitive Landscape
- Merck & Co., Inc. (Merck Animal Health)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ceva
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Zoetis Services LLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Boehringer Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Indian Immunologicals Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bioveta, a.s.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Komipharm
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- EC21 Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Merck & Co., Inc. (Merck Animal Health)
- Analyst Recommendation
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
- Section
- References
- Research Methodology
- About Us and Sales Contact
Detailed Segmentation:
- Global Swine Fever Vaccine Market, By Type:
- African Swine Fever
- Classical Swine Fever
- Global Swine Fever Vaccine Market, By Vaccine Type:
- Live-Attenuated
- Chimeric (Live-attenuated or inactivated)
- Subunit or vector system based
- Replicon vaccine
- Global Swine Fever Vaccine Market, By Distribution Channel:
- Public
- Private
- Global Swine Fever Vaccine Market, By Region:
- North America
- By Type
- African Swine Fever
- Classical Swine Fever
- By Vaccine Type
- Live-Attenuated
- Chimeric (Live-attenuated or inactivated)
- Subunit or vector system based
- Replicon vaccine
- By Distribution Channel
- Public
- Private
- By Country
- U.S.
- Canada
- By Type
- Latin America
- By Type
- African Swine Fever
- Classical Swine Fever
- By Vaccine Type
- Live-Attenuated
- Chimeric (Live-attenuated or inactivated)
- Subunit or vector system based
- Replicon vaccine
- By Distribution Channel
- Public
- Private
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Type
- Europe
- By Type
- African Swine Fever
- Classical Swine Fever
- By Vaccine Type
- Live-Attenuated
- Chimeric (Live-attenuated or inactivated)
- Subunit or vector system based
- Replicon vaccine
- By Distribution Channel
- Public
- Private
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Type
- Asia Pacific
- By Type
- African Swine Fever
- Classical Swine Fever
- By Vaccine Type
- Live-Attenuated
- Chimeric (Live-attenuated or inactivated)
- Subunit or vector system based
- Replicon vaccine
- By Distribution Channel
- Public
- Private
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Type
- Middle East
- By Type
- African Swine Fever
- Classical Swine Fever
- By Vaccine Type
- Live-Attenuated
- Chimeric (Live-attenuated or inactivated)
- Subunit or vector system based
- Replicon vaccine
- By Distribution Channel
- Public
- Private
- By Country
- GCC
- Israel
- Rest of Middle East
- By Type
- Africa
- By Type
- African Swine Fever
- Classical Swine Fever
- By Vaccine Type
- Live-Attenuated
- Chimeric (Live-attenuated or inactivated)
- Subunit or vector system based
- Replicon vaccine
- By Distribution Channel
- Public
- Private
- By Region
- South Africa
- Central Africa
- North Africa
- By Type
- North America